FrancophonIA/ELRC3.0 huggingface dataset:
English: Adult dose should be reduced to 25 mg every 12 hours following the 100 mg loading dose.
Slovenian: Odmerek za odrasle je treba, po polnilnem odmerku 100 mg, zmanjšati na 25 mg vsakih 12 ur.
English: Tigecycline in recommended dosage did not affect the rate or extent of absorption, or clearance of digoxin (0.5 mg followed by 0.25 mg daily) when administered in healthy adults.
Slovenian: Ko so tigeciklin v priporočenih odmerkih (0,5 mg, nato 0,25 mg na dan) dajali zdravim odraslim, ni vplival na hitrost ali obseg absorpcije, niti na očistek digoksina.
English: Tygacil 50 mg powder for infusion Tigecycline
Slovenian: Tygacil 50 mg prašek za raztopino za infundiranje tigeciklin
English: Tygacil may cause side effects such as dizziness.
Slovenian: Zdravilo Tygacil lahko povzroči neželene učinke, kot na primer omotico.
English: • Anaphylaxis/anaphylactoid reactions (that may range from mild to severe, including a sudden,
Slovenian: • anafilaksija/anafilaktoidne reakcije (ki so lahko blage do težke, vključno z nenadno generalizirano alergijsko reakcijo, ki lahko povzroči smrtno nevaren šok [npr. oteženo dihanje,
English: Each 5 ml Tygacil vial contains 50 mg of tigecycline.
Slovenian: Ena 5-mililitrska viala zdravila Tygacil vsebuje 50 mg tigeciklina.
English: Viridans group streptococci
Slovenian: Streptokoki skupine viridans
English: Consideration should be given to the use of combination antibacterial therapy whenever tigecycline is to be administered to severely ill patients with cIAI secondary to clinically apparent intestinal perforation or patients with incipient sepsis or septic shock (see section 4.8).
Slovenian: Kadarkoli nameravamo dati tigeciklin hudo bolnim bolnikom s cIAI, ki so nastale zaradi klinično očitne perforacije črevesa, ali bolnikom z začetno sepso ali septičnim šokom, moramo pretehtati možnost kombiniranega protibakterijskega zdravljenja (glejte poglavje 4.8).
English: Peptostreptococcus spp.†
Slovenian: Clostridium perfringens† Peptostreptococcus spp.† Prevotella spp.
English: Liver function tests, coagulation parameters, haematology parameters, amylase and lipase should be monitored prior to treatment initiation with tigecycline and regularly while on treatment.
Slovenian: Pred uvedbo zdravljenja s tigeciklinom in redno med zdravljenjem je treba spremljati izvide testov jetrne funkcije, koagulacijske parametre, hematološke parametre, amilazo in lipazo.
English: • Pruritus (itching), rash
Slovenian: • pruritus (srbenje), kožni izpuščaj
English: Race There were no differences in the clearance of tigecycline based on race.
Slovenian: Rasa Očistek tigeciklina se med pripadniki različnih ras ni razlikoval.
English: Talk to your doctor or nurse before receiving Tygacil:
Slovenian: Pred začetkom prejemanja zdravila Tygacil se posvetujte z zdravnikom ali medicinsko sestro:
English: No evidence of photosensitivity was observed in rats following administration of tigecycline.
Slovenian: Po uporabi tigeciklina niso pri podganah opazili nikakršnih dokazov preobčutljivosti za svetlobo.
English: The vial should be gently swirled until the active substance is dissolved.
Slovenian: Vialo nežno vrtite, dokler se zdravilna učinkovina ne raztopi.
English: C-tigecycline, unchanged tigecycline was the primary
Slovenian: C-tigeciklin, primarna snov, označena s
English: If the same intravenous line is used for sequential infusion of several active substances, the line should be flushed before and after infusion of tigecycline with either sodium chloride 9 mg/ml (0.9 %) solution for injection or dextrose 50 mg/ml (5 %) solution for injection.
Slovenian: Tigeciklin morate aplicirati intravensko po ločenem infuzijskem kanalu ali skozi podaljšek Y. Če uporabljate intravenski kanal za zaporedno infundiranje več različnih učinkovin, ga morate pred infuzijo tigeciklina in po njej splakniti bodisi z 0,9-odstotno (9 mg/ml) raztopino natrijevega klorida za injiciranje bodisi s 5-odstotno (50 mg/ml) raztopino glukoze za injiciranje.
English: The single-dose pharmacokinetic disposition of tigecycline was not altered in patients with mild hepatic impairment.
Slovenian: Pri bolnikih z blago okvaro jeter se farmakokinetika tigeciklina po enkratnem odmerku ni spremenila.
English: • Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections (see section 4.4);
Slovenian: • zapletene okužbe kože in mehkih tkiv (complicated skin and soft tissue infections - cSSTI),
English: Tygacil is distributed in a ten vial tray pack.
Slovenian: Zdravilo Tygacil je na voljo v škatli s podstavkom z desetimi vialami.
English: Tygacil may interfere with the contraceptive pill (birth control pill).
Slovenian: Zdravilo Tygacil lahko zmanjša delovanje kontracepcijskih tablet.
English: Ask your doctor for advice before breast-feeding your baby.
Slovenian: Preden začnete dojiti svojega otroka, se posvetujte z zdravnikom.
English: Lactose monohydrate Hydrochloric acid
Slovenian: 6.1 Seznam pomožnih snovi laktoza monohidrat klorovodikova kislina natrijev hidroksid (za uravnavanje pH)
English: generalised allergic reaction that may lead to a life-threatening shock [e.g. difficulty in breathing, drop of blood pressure, fast pulse]).
Slovenian: padec krvnega tlaka, pospešen srčni utrip])
English: Pfizer Luxembourg SARL Pfizer, podružnica za svetovanje s področja farmacevtske dejavnosti, Ljubljana Tel.: + 386 (0) 1 52 11 400
Slovenian: Pfizer Luxembourg SARL Pfizer, podružnica za svetovanje s področja farmacevtske dejavnosti, Ljubljana
English: Tetracycline class effects
Slovenian: Učinki zdravil iz skupine tetraciklinov
English: What Tygacil contains The active substance is tigecycline.
Slovenian: Zdravilna učinkovina je tigeciklin.
English: Consideration should be given to the cessation of the treatment with tigecycline in cases suspected of having developed pancreatitis.
Slovenian: Kadar posumimo, da se razvija pankreatitis, moramo razmisliti o prekinitvi zdravljenja s tigeciklinom.
English: For non-oncology indications:
Slovenian: Za neonkološke indikacije:
English: As the Patient Alert Card is part of the product information in the outer packaging, the content will be centrally approved for all EU/EEA languages without need of further approval by National Authorities.
Slovenian: Ker je opozorilna kartica za bolnika del povzetka glavnih značilnosti zdravila v zunanjem pakiranju, bo vsebina centralno odobrena za vse jezike EU/EGS, pri čemer dodatna odobritev s strani nacionalnih organov ni potrebna.
English: • Periodic safety update reports (PSUR)
Slovenian: • Redno posodobljena poročila o varnosti zdravila (PSUR)
English: A Patient Alert Card will be included in the carton.
Slovenian: Opozorilna kartica za bolnika bo priložena v škatli.
English: Do not have Riximyo if you have an active infection or a serious problem with your immune system.
Slovenian: Zdravila Riximyo ne smete prejeti, če imate aktivno okužbo ali resno težavo s svojim imunskim sistemom.
English: Patients should receive Riximyo for at least 24 months after achievement of remission (absence of clinical signs and symptoms).
Slovenian: Riximyo prejemati vsaj 24 mesecev po doseženi remisiji (odsotnost kliničnih znakov in simptomov).
English: • Show this card to any doctor, nurse or dentist you see - not just the specialist who prescribes your Riximyo.
Slovenian: • Pokažite jo vsem zdravnikom, medicinskim sestram in zobozdravnikom, ki jih obiščete - ne samo specialistu, ki vam predpiše zdravilo Riximyo.
English: Your doctor may decide to treat you longer with Riximyo (up to 5 years), depending on how you respond to the medicine.
Slovenian: Zdravnik se lahko odloči, da vas bo z zdravilom Riximyo zdravil dlje (do 5 let), odvisno od tega, kako se odzovete na zdravilo.
English: Riximyo may also cause changes in laboratory tests carried out by your doctor.
Slovenian: Zdravilo Riximyo lahko vpliva tudi na spremembe laboratorijskih preiskav, ki jih naroči vaš zdravnik.
English: Your doctor may decide to stop your Riximyo treatment if these reactions are serious.
Slovenian: Zdravnik se lahko odloči za prenehanje zdravljenja z zdravilom Riximyo, če so te reakcije resne.
English: Currently, there are limited data on possible interactions with other medicinal products and rituximab.
Slovenian: Trenutno je le malo podatkov o mogočih medsebojnih učinkih drugih zdravil in rituksimaba.
English: Riximyo will be given to you by a doctor or nurse who is experienced in the use of this treatment.
Slovenian: Zdravilo Riximyo vam bo dal zdravnik ali medicinska sestra, ki ima izkušnje z uporabo takšnih zdravil.
English: Efficacy was observed both for patients with newly diagnosed disease and for patients with relapsing disease (Table 13).
Slovenian: Učinkovitost so ugotovili tako pri bolnikih z novoodkrito boleznijo kot pri bolnikih s ponovitvijo bolezni (preglednica 13).
English: If you can get pregnant, you and your partner must use an effective method of contraception while using Riximyo.
Slovenian: Če bi lahko zanosili, morate vi in vaš partner med uporabo zdravila Riximyo uporabljati učinkovito kontracepcijsko zaščito.
English: Before you are given Riximyo you will be given other medicines (premedication) to prevent or reduce possible side effects.
Slovenian: Preden boste dobili zdravilo Riximyo, boste dobili druga zdravila (to imenujemo premedikacija) za preprečitev ali zmanjšanje možnih neželenih učinkov.
English: Riximyo in combination with chemotherapy destroys these cells which are gradually removed from the body by biological processes.
Slovenian: Zdravilo Riximyo v kombinaciji s kemoterapijo uniči te celice, ki se postopno odstranijo iz telesa z biološkimi procesi.
English: Patients reporting signs and symptoms of infection following Riximyo therapy should be promptly evaluated and treated appropriately.
Slovenian: Bolnike, pri katerih se pojavijo znaki in simptomi okužbe po zdravljenju z zdravilom Riximyo, je treba nemudoma pregledati in primerno zdraviti.
English: Riximyo is indicated in adults for the following indications:
Slovenian: Zdravilo Riximyo je pri odraslih indicirano za naslednje indikacije:
English: p-value (Wald test,
Slovenian: p-vrednost (test Wald, ni prilagojen)
English: For these reasons Riximyo should not be administered to pregnant women unless the possible benefit outweighs the potential risk.
Slovenian: Zato nosečnice ne smejo prejemati zdravila Riximyo, razen če je pričakovana korist večja od možnega tveganja.
English: Rarely Riximyo can cause a serious brain infection, called “Progressive Multifocal Leukoencephalopathy” or PML.
Slovenian: Redko lahko zdravilo Riximyo povzroči resno možgansko okužbo, imenovano progresivna multifokalna levkoencefalopatija ali PML.
English: Vaccination should be completed at least 4 weeks prior to first administration of Riximyo.
Slovenian: Cepljenje naj bo zaključeno najmanj 4 tedne pred prvo aplikacijo zdravila Riximyo.
English: Hazard ratio (95% CI)
Slovenian: Razmerje ogroženosti (95-% CI)
English: Before giving a subsequent course of Riximyo treatment, patients should be re-evaluated for any potential risk for infections.
Slovenian: Pred dajanjem nadaljnjega cikla zdravila Riximyo je treba bolnike ponovno oceniti glede možnega tveganja za okužbe.
English: Your doctor will check if you should have any vaccines before you receive Riximyo.
Slovenian: Vaš zdravnik bo preveril, ali bi morali biti cepljeni, preden boste dobili zdravilo Riximyo.
English: The HCP educational leafletsand the Patient educational leaflet will be agreed with the National Competent Authorities prior to distribution.
Slovenian: O izobraževalnih letakih za zdravstvenega delavca in izobraževalnih letakih za bolnika bo pred razdelitvijo dogovorjeno z nacionalnim organom, pristojnim za zdravila.
English: < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000) and not known (cannot be estimated from the available data).
Slovenian: pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
English: Riximyo should be administered under the close supervision of an experienced healthcare professional, and in an environment where full resuscitation facilities are immediately available (see section 4.4).
Slovenian: Zdravilo Riximyo je treba dajati pod nadzorom izkušenega zdravnika in v okolju, kjer so vsi pripomočki za oživljanje nemudoma na voljo (glejte poglavje 4.4).
English: Table 12 Percentage of patients who achieved complete remission at 6 months (intent-to-treat population*)
Slovenian: Odstotek bolnikov, ki so po 6 mesecih dosegli popolno remisijo (populacija, ki so jo nameravali zdraviti*)
English: This should be followed by oral prednisone 1 mg/kg/day (not to exceed 80 mg/day, and tapered as rapidly as possible based on clinical need) during and after the 4 week induction course of Riximyo treatment.
Slovenian: 1 mg/kg/dan prednizona peroralno (odmerek ne sme preseči 80 mg/dan in ga je treba zmanjšati, kolikor hitro je mogoče glede na klinične potrebe) med in po 4-tedenskem indukcijskem zdravljenju z zdravilom Riximyo.
English: • If you respond well to treatment, you may be given Riximyo as a maintenance treatment every 2 or 3 months for two years.
Slovenian: • Če se boste dobro odzvali na zdravljenje, boste lahko zdravilo Riximyo dobivali kot vzdrževalno zdravljenje na dva meseca ali tri, in sicer dve leti.
English: • hives, increased sweating, night sweats
Slovenian: • koprivnica, močnejše znojenje, nočno znojenje,
English: The cells that are affected by Riximyo help to fight infection and you should wait until the infection has passed before you are given Riximyo.
Slovenian: Celice, ki jih zdravilo Riximyo uniči, pomagajo pri borbi proti okužbam, zato morate počakati, da se okužba pozdravi, preden prejmete zdravilo Riximyo.
English: In patients where the treatment is working, Riximyo may be used as a maintenance treatment for 2 years after completing the initial treatment.
Slovenian: Pri bolnikih, pri katerih takšno zdravljenje deluje, je mogoče zdravilo Riximyo uporabljati kot vzdrževalno zdravljenje še dve leti po dokončanju začetnega zdravljenja.
English: If a patient develops PML, the dosing of Riximyo must be permanently discontinued.
Slovenian: Če se pri bolniku razvije PML, je treba uporabo zdravila Riximyo dokončno ukiniti.
English: For each term, the frequency count was based on reactions of all grades (from mild to severe), except for terms marked with "+" where the frequency count was based only on severe (≥ grade 3 NCI common toxicity criteria)
Slovenian: Pri vsakem izrazu so pri določitvi pogostnosti upoštevali neželene učinke vseh stopenj (od blage do hude), razen za izraze, označene s "+", kjer so pri določitvi pogostnosti upoštevali le hude neželene učinke (≥ 3. stopnja po lestvici skupnih meril toksičnosti Nacionalnega inštituta za raka (NCI common toxicity criteria)).
English: Measure blood neutrophils prior to each course of Riximyo, and regularly up to 6-months after cessation of treatment, and upon signs or symptoms of infection (see section 4.8).
Slovenian: Število nevtrofilcev v krvi je treba določiti pred vsakim ciklom zdravila Riximyo in redno do 6 mesecev po končanem zdravljenju ter pri znakih ali simptomih okužbe (glejte poglavje 4.8).
English: Rituximab may have a minor influence on the ability to drive and use machines.
Slovenian: Rituksimab ima lahko blag vpliv na sposobnost vožnje in upravljanja strojev.
English: • nerve damage in arms and legs, paralysed face
Slovenian: • okvara živcev v rokah in nogah, paraliza obraza,
English: Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to
Slovenian: Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10),
English: If you respond well to treatment, you may be given Riximyo as a maintenance treatment.
Slovenian: Če se boste na zdravilo dobro odzvali, boste lahko zdravilo Riximyo prejemali kot vzdrževalno zdravljenje.
English: • asthma, too little oxygen reaching the body organs
Slovenian: • astma, telesne organe doseže premalo kisika, • oteklost trebuha.
English: Contents of the pack and other information What Riximyo contains
Slovenian: Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Riximyo
English: Some vaccines should not be given at the same time as Riximyo or in the months after you receive Riximyo.
Slovenian: Nekatera cepiva se ne smejo dajati sočasno z zdravilom Riximyo ali nekaj mesecev po prejetju tega zdravila.
English: Binet stage A Binet stage B Binet stage C CI: Confidence Interval
Slovenian: stopnja po Binetu A stopnja po Binetu B stopnja po Binetu C
English: Riximyo is for intravenous use.
Slovenian: Zdravilo Riximyo je za intravensko uporabo.
English: Therefore vaccination with live virus vaccines is not recommended whilst on Riximyo or whilst peripherally B cell depleted.
Slovenian: Cepljenje z živimi virusnimi cepivi zato ni priporočljivo med zdravljenjem z zdravilom Riximyo ali medtem, ko je število perifernih celic B zmanjšano.
English: When you are treated with Riximyo in combination with chemotherapy, you will receive Riximyo infusions on day 0 cycle 1 then day 1 of each cycle for 6 cycles in total.
Slovenian: Ko se boste zdravili z zdravilom Riximyo v kombinaciji s kemoterapijo, boste dobili infuzijo zdravila Riximyo 0. dan 1. cikla in nato 1. dan vsakega naslednjega cikla, skupaj 6 ciklov.
English: This is because Riximyo may pass into breast milk.
Slovenian: Zdravilo Riximyo namreč lahko prehaja v materino mleko.
English: This is because in a few cases, Riximyo could cause hepatitis B to become active again, which can be fatal in very rare cases.
Slovenian: V maloštevilnih primerih namreč lahko bolezen zaradi zdravila Riximyo ponovno izbruhne; to je lahko v zelo redkih primerih smrtno.
English: Figure 2: Number of patients who were off or on minimal corticosteroid (≤10mg/day) therapy over time
Slovenian: Slika 2: Število bolnikov brez kortikosteroidnega zdravljenja ali z minimalnim kortikosteroidnim zdravljenjem (≤ 10 mg/dan) glede na čas zdravljenja
English: Talk to your doctor, pharmacist or nurse before you are given Riximyo if:
Slovenian: Posvetujte se z zdravnikom, farmacevtom ali medicinsko sestro, preden dobite zdravilo Riximyo:
English: Other medicines and Riximyo
Slovenian: Druga zdravila in zdravilo Riximyo
English: Riximyo 500 mg concentrate for solution for infusion EU/1/17/1184/003
Slovenian: Riximyo 500 mg koncentrat za raztopino za infundiranje EU/1/17/1184/003
English: When should I not have Riximyo?
Slovenian: Kdaj ne smete prejeti zdravila Riximyo?
English: OSHO-39 MCP, 96 R-MCP, 105 47
Slovenian: MCP: 96 R-MCP: 105
English: Riximyo 100 mg concentrate for solution for infusion EU/1/17/1184/001
Slovenian: Riximyo 100 mg koncentrat za raztopino za infundiranje EU/1/17/1184/001
English: Cumulative incidence over time of first major relapse
Slovenian: Slika 1: Kumulativna incidenca glede na čas prvega hujšega recidiva
English: If you are having Riximyo with other medicines, some of the side effects you may get may be due to the other medicines.
Slovenian: Če prejemate zdravilo Riximyo skupaj z drugimi zdravili, se nekateri neželeni učinki lahko pojavijo zaradi drugih zdravil.
English: No dose reductions of Riximyo are recommended.
Slovenian: Odmerka zdravila Riximyo ni priporočljivo zmanjšati.
English: Reactivation of hepatitis B infection has also been very rarely reported in RA patients receiving rituximab (see section 4.4).
Slovenian: O reaktivaciji okužbe z virusom hepatitisa B so zelo redko poročali tudi pri bolnikih z revmatoidnim artritisom, ki so prejemali rituksimab (glejte poglavje 4.4).
English: Your doctor may need to take special care of you during your treatment with Riximyo.
Slovenian: Zdravnik bo morda moral med zdravljenjem z zdravilom Riximyo posebej poskrbeti za vas.
English: Riximyo should not be administered to patients with an active, severe infection (e.g. tuberculosis, sepsis and opportunistic infections, see section 4.3) or severely immunocompromised patients (e.g. where levels of CD4 or CD8 are very low).
Slovenian: Zdravila Riximyo se ne sme dajati bolnikom z aktivno, hudo okužbo (npr. tuberkulozo, sepso ali oportunističnimi okužbami, glejte poglavje 4.3) ali hudo imunokompromitiranim bolnikom (npr. pri zelo nizkih vrednostih CD4 ali CD8).
English: Minor relapses (not life threatening and not involving major organ damage) occurred in seven patients in the rituximab group (12%) and eight patients in the azathioprine group (14%).
Slovenian: Blažji recidivi (takšni, ki niso bili življenjsko ogrožajoči in niso vključevali okvare pomembnega organa) so se pojavili pri sedmih bolnikih v skupini z rituksimabom (12 %) in pri osmih bolnikih v skupini z azatioprinom (14 %).
English: The trial demonstrated non-inferiority of rituximab to cyclophosphamide for complete remission (CR) at 6 months (Table 12).
Slovenian: Preskušanje je dokazalo neinferiornost rituksimaba v primerjavi s ciklofosfamidom glede popolne remisije po 6 mesecih (preglednica 12).
English: • pain in the muscles
Slovenian: • bolečina v mišicah,
English: The cumulative incidence rate curves showed that time to first major relapse was longer in patients with rituximab starting from month 2 and was maintained up to month 28 (Figure 1).
Slovenian: Krivulje kumulativnih stopenj incidence so pokazale, da je bil čas do prvega hujšega recidiva pri bolnikih, ki so prejemali rituksimab, daljši, in sicer od 2. meseca naprej; to se je ohranilo do 28. meseca (slika 1).
English: Riximyo is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
Slovenian: Zdravilo Riximyo je indicirano za zdravljenje bolnikov s CD20-pozitivnim difuznim velikoceličnim B ne-Hodgkinovim limfomom v kombinaciji s kemoterapijo CHOP (ciklofosfamid, doksirubicin, vinkristin, prednizolon).
English: Following induction of remission with Riximyo, maintenance treatment should be initiated no sooner than 16 weeks after the last rituximab infusion.
Slovenian: Po indukciji remisije z zdravilom Riximyo se vzdrževalno zdravljenje ne sme začeti prej kot 16 tednov po zadnji infuziji rituksimaba.
English: For patients who may be at higher risk for relapse, physicians should consider a longer duration of Riximyo maintenance therapy, up to 5 years.
Slovenian: Pri bolnikih z večjim tveganjem za recidiv je treba razmisliti o dolgotrajnejšem vzdrževalnem zdravljenju z zdravilom Riximyo, do 5 let.
English: Riximyo may be used for the treatment of several different conditions in adults.
Slovenian: Zdravilo Riximyo se uporablja za zdravljenje več različnih bolezni pri odraslih.
English: Your doctor may prescribe Riximyo for the treatment of:
Slovenian: Zdravnik vam lahko zdravilo Riximyo predpiše za zdravljenje:
English: No incompatibilities between Riximyo and polyvinyl chloride or polyethylene bags or infusion sets have been observed.
Slovenian: Med zdravilom Riximyo in vrečkami iz polivinilklorida ali polietilena ali infuzijskimi seti niso ugotovili inkompatibilnosti.
English: Aseptically withdraw the necessary amount of Riximyo, and dilute to a calculated concentration of 1 to 4 mg/mL rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/mL (0.9%) solution for injection or 5% D-Glucose in water.
Slovenian: Aseptično odvzamemo potrebno količino zdravila Riximyo in jo razredčimo, da dobimo izračunano koncentracijo od 1 do 4 mg/ml rituksimaba v infuzijski vrečki, ki vsebuje sterilno apirogeno 0,9-% raztopino natrijevega klorida za injiciranje (9 mg/ml) ali 5-% raztopino D-glukoze v vodi.
English: When Riximyo is given in combination with chemotherapy, standard dose reductions for the chemotherapeutic medicinal products should be applied.
Slovenian: Če zdravilo Riximyo uporabimo v kombinaciji s kemoterapijo, je treba uporabiti standardno zmanjšanje odmerkov citostatikov.
English: Rituximab may make you feel dizzy and may affect your ability to drive or use any tools or machines.
Slovenian: Rituksimab lahko povzroči omotičnost in vpliva na vašo sposobnost za upravljanje vozil ali strojev.